.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,316,426

« Back to Dashboard

Details for Patent: 6,316,426

Title: Acylated uridine and cytidine and uses thereof
Abstract:The invention relates to compositions comprising acyl derivatives of cytidine and uridine. The invention also relates to methods of treating hepatopathies, diabetes, heart disease, cerebrovascular disorders, Parkinson's disease, infant respiratory distress syndrome and for enhancement of phospholipid biosynthesis comprising administering the acyl derivatives of the invention to an animal.
Inventor(s): von Borstel; Reid Warren (Darnestown, MD), Bamat; Michael Kevin (Darnestown, MD)
Assignee: Pro-Neuron, Inc. (Gaithersburg, MD)
Filing Date:Jun 06, 1995
Application Number:08/466,144
Claims:1. A method for treating a central nervous system disorder comprising administering to an animal in need of such treatment an acyl derivative of uridine in an amount to effect such treatment, having the formula (I) ##STR4##

wherein R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are the same or different and each is hydrogen or an acyl radical or a carboxylic acid selected from the group consisting of glycolic acid, pyruvic acid, lactic acid, enolpyruvic acid, an amino acid, a fatty acid of 2 to 22 carbon atoms, lipoic acid, pantothenic acid, succinic acid, fumaric acid, adipic acid, acetoacetic acid, p-aminobenzoic acid, betahydroxybutyric acid, orotic acid, and creatine, provided that at least one of said R substituents is not hydrogen, or a pharmaceutically acceptable salt thereof.

2. A method as recited in claim 1 wherein said acyl derivative of uridine is administered orally.

3. A method as in claim 1 wherein said acyl derivative of uridine has the formula (I) wherein R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are the same or different and each is hydrogen or an acyl radical of a fatty acid of 2 to 22 carbon atoms, provided that at least one of said R substituents is not hydrogen.

4. A method as recited in claim 3 wherein said acyl derivative of uridine is selected from the group consisting of 2',3', 5'-tri-0-acetyl uridine, 2',3',5'-tri-0-propionyl uridine, and 2',3',5'-tri-0-butyryl uridine.

5. A method as recited in claim 4 wherein said acyl derivative of uridine is 2', 3', 5'-tri-acetyl uridine.

6. A method as in claim 5 wherein said acyl derivative of uridine is administered orally.

7. A method as in claim 1 wherein said acyl derivative of uridine is administered in a dose of 15-4500 mg.

8. A method as in claim 7 wherein said acyl derivative of uridine is 2',3',5'-tri-acetyl uridine, and said dose is administered 1-3 times per day.

9. A method as in claim 1 wherein said central nervous system disorder is a cerebrovascular disorder.

10. A method as in claim 9 wherein said cerebrovascular disorder is stroke or chronic or acute cerebrovascular insufficiency.

11. A method as in claim 9 wherein said cerebrovascular disorder is cerebrovascular dementia.

12. A method as in claim 1 wherein said central nervous system disorder is senile dementia.

13. A method as in claim 1 wherein said central nervous system disorder is Parkinson's disease.

14. A method as in claim 13 further comprising administering L-DOPA.

15. A method as in claim 1 wherein said central nervous system disorder is cerebral ataxia.

16. A method as in claim 1 wherein said central nervous system disorder is seizures.

17. A method as in claim 1 further comprising administering an acyl derivative of cytidine.

18. A method for treating a central nervous system disorder comprising administering to an animal in need of such treatment an acyl derivative of cytidine in an amount to effect such treatment, having the formula (III) ##STR5##

wherein R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are the same or different and each is hydrogen or an acyl radical of a carboxylic acid selected from the group consisting of glycolic acid, pyruvic acid, lactic acid, enolpyruvic acid, an amino acid, a fatty acid of 2 to 22 carbon atoms, lipoic acid, pantothenic acid, succinic acid, fumaric acid, adipic acid, acetoacetic acid, p-aminobenzoic acid, betahydroxybutyric acid, orotic acid, and creatine, provided that at least one of said R substituents is not hydrogen, and that R.sub.4 is not a fatty acid, or a pharmaceutically acceptable salt thereof.

19. A method as recited in claim 18 wherein said acyl derivative of cytidine is administered orally.

20. A method as in claim 18 wherein said acyl derivative of cytidine has the formula (III) wherein R.sub.2, R.sub.2, R.sub.3, and R.sub.4 are the same or different and each is hydrogen or an acyl radical of a fatty acid 2 to 22 carbon atoms, provided that at least one of said R substituents is not hydrogen.

21. A method as recited in claim 20 wherein said acyl derivative of cytidine is selected from the group consisting of 2',3',5'-tri-0-acetyl cytidine, 2',3',5'-tri-0-propionyl cytidine, and 2',3',5'-tri-0-butyryl cytidine.

22. A method as in claim 21 wherein said acyl derivative of cytidine is administered orally.

23. A method as in claim 18 wherein said central nervous system disorder is a cerebrovascular disorder.

24. A method as in claim 18 wherein said cerebrovascular disorder is stroke or chronic or acute cerebrovascular insufficiency.

25. A method as in claim 18 wherein said cerebrovascular disorder is cerebrovascular dementia.

26. A method as in claim 18 wherein said central nervous system disorder is senile dementia.

27. A method as in claim 18 wherein said central nervous system disorder is Parkinson's disease.

28. A method as in claim 18 further comprising administering L-DOPA.

29. A method as in claim 18 wherein said central nervous system disorder is cerebral ataxia.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc